Story thread · 2 reports / 2 sources
Harbour BioMed Partner, Solstice Oncology, announces $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy
laotiantimes.com · 5d
Porustobart, a second-generation Fc-enhanced CTLA-4 antibody, is being advanced across two clinical indications in the neoadjuvant setting, beginning with MSS clinical stage II-III colon cancer Phase 2 trial of porustobart for colon cancer will be open for enrollment early in the fourth quarter of 2026 Financing led by RA Capital Management, joined by Canaan Partners, […]
First report: A new immuno-oncology play raises $225M for a next-generation drug — biopharmadive.com, 5d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.